LC and TLC determination of cinnarizine in pharmaceutical preparations and serum
New high performance liquid chromatography (HPLC) and thin layer densitometry (TLC) methods are developed for quantification of cinnarizine in dosage forms in the presence of its photo-degradation products and related substances and in the presence of its metabolites in serum. Mobile phases consisti...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2002-05, Vol.28 (3), p.711-719 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 719 |
|---|---|
| container_issue | 3 |
| container_start_page | 711 |
| container_title | Journal of pharmaceutical and biomedical analysis |
| container_volume | 28 |
| creator | Hassan, Saad S.M Elmosallamy, Mohamed A.F Abbas, Alaa B |
| description | New high performance liquid chromatography (HPLC) and thin layer densitometry (TLC) methods are developed for quantification of cinnarizine in dosage forms in the presence of its photo-degradation products and related substances and in the presence of its metabolites in serum. Mobile phases consisting of benzene–methanol–formic acid (80:17:3) and methanol–acetate buffer of pH 4 (70:30) are satisfactorily used for resolution of cinnarizine from associated substances by TLC and HPLC techniques, respectively. The lower detection limits are 16 and 10 ng μl
−1 of cinnarizine with standard deviations of 1.3 and 1.1% with TLC and HPLC, respectively. The methods are used for assessment of drug purity, stability, bioavailability, bioequivalency and tablet dissolution rate. Four cinnarizine related substances and six drug degradation products are isolated and identified by infrared and mass spectrometry. The results obtained by both techniques are in good agreement and offer the advantages of reproducibility and accuracy. |
| doi_str_mv | 10.1016/S0731-7085(01)00662-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71681323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708501006628</els_id><sourcerecordid>71681323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-7054f88fef40161206a51a6123b7402fb3ec844a6bf8df3a39d12b7e1f3176fd3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMouq7-BKUXRQ_VTNOm2ZPI4hcsKLiCt5CmE4xs05q0gv56sx_o0dPM4ZmZdx5CjoBeAAV--UxLBmlJRXFG4ZxSzrNUbJERiJKlGc9ft8noF9kj-yG8U0oLmOS7ZA8ySgUUMCJPs2miXJ3MY62xR99Yp3rbuqQ1ibbOKW-_rcPEuqR7U75RGofearVIOo-d8is4rHYE9ENzQHaMWgQ83NQxebm9mU_v09nj3cP0epZqNoE-pipyI4RBk8dvYh6uClCxYVWZ08xUDLXIc8UrI2rDFJvUkFUlgmFQclOzMTld7-18-zFg6GVjg8bFQjlshyBL4AJYxiJYrEHt2xA8Gtl52yj_JYHKpUq5UimXniQFuVIpRZw73hwYqgbrv6mNuwicbAAVog_jldM2_HGMi6wEGrmrNYdRx6dFL4O26DTW1qPuZd3af6L8AK02j60</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71681323</pqid></control><display><type>article</type><title>LC and TLC determination of cinnarizine in pharmaceutical preparations and serum</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hassan, Saad S.M ; Elmosallamy, Mohamed A.F ; Abbas, Alaa B</creator><creatorcontrib>Hassan, Saad S.M ; Elmosallamy, Mohamed A.F ; Abbas, Alaa B</creatorcontrib><description>New high performance liquid chromatography (HPLC) and thin layer densitometry (TLC) methods are developed for quantification of cinnarizine in dosage forms in the presence of its photo-degradation products and related substances and in the presence of its metabolites in serum. Mobile phases consisting of benzene–methanol–formic acid (80:17:3) and methanol–acetate buffer of pH 4 (70:30) are satisfactorily used for resolution of cinnarizine from associated substances by TLC and HPLC techniques, respectively. The lower detection limits are 16 and 10 ng μl
−1 of cinnarizine with standard deviations of 1.3 and 1.1% with TLC and HPLC, respectively. The methods are used for assessment of drug purity, stability, bioavailability, bioequivalency and tablet dissolution rate. Four cinnarizine related substances and six drug degradation products are isolated and identified by infrared and mass spectrometry. The results obtained by both techniques are in good agreement and offer the advantages of reproducibility and accuracy.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/S0731-7085(01)00662-8</identifier><identifier>PMID: 12008151</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Animals ; Bioavailability ; Bioequivalency ; Biological and medical sciences ; Calibration ; Chromatography, High Pressure Liquid ; Chromatography, Thin Layer ; Cinnarizine - analysis ; Cinnarizine - blood ; Cinnarizine - pharmacokinetics ; Cinnarizine assay ; Cinnarizine photo- and acid-degradation products ; Densitometry ; Female ; General pharmacology ; High performance liquid chromatography ; Histamine H1 Antagonists - analysis ; Histamine H1 Antagonists - blood ; Histamine H1 Antagonists - pharmacokinetics ; Indicators and Reagents ; Kinetics ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Rats ; Rats, Sprague-Dawley ; Solubility ; Spectrophotometry, Infrared ; Spectrophotometry, Ultraviolet ; Tablet dissolution rate ; Tablets ; Therapeutic Equivalency ; Thin layer densitometry</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2002-05, Vol.28 (3), p.711-719</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-7054f88fef40161206a51a6123b7402fb3ec844a6bf8df3a39d12b7e1f3176fd3</citedby><cites>FETCH-LOGICAL-c391t-7054f88fef40161206a51a6123b7402fb3ec844a6bf8df3a39d12b7e1f3176fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0731708501006628$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13682710$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12008151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hassan, Saad S.M</creatorcontrib><creatorcontrib>Elmosallamy, Mohamed A.F</creatorcontrib><creatorcontrib>Abbas, Alaa B</creatorcontrib><title>LC and TLC determination of cinnarizine in pharmaceutical preparations and serum</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>New high performance liquid chromatography (HPLC) and thin layer densitometry (TLC) methods are developed for quantification of cinnarizine in dosage forms in the presence of its photo-degradation products and related substances and in the presence of its metabolites in serum. Mobile phases consisting of benzene–methanol–formic acid (80:17:3) and methanol–acetate buffer of pH 4 (70:30) are satisfactorily used for resolution of cinnarizine from associated substances by TLC and HPLC techniques, respectively. The lower detection limits are 16 and 10 ng μl
−1 of cinnarizine with standard deviations of 1.3 and 1.1% with TLC and HPLC, respectively. The methods are used for assessment of drug purity, stability, bioavailability, bioequivalency and tablet dissolution rate. Four cinnarizine related substances and six drug degradation products are isolated and identified by infrared and mass spectrometry. The results obtained by both techniques are in good agreement and offer the advantages of reproducibility and accuracy.</description><subject>Analysis</subject><subject>Animals</subject><subject>Bioavailability</subject><subject>Bioequivalency</subject><subject>Biological and medical sciences</subject><subject>Calibration</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Chromatography, Thin Layer</subject><subject>Cinnarizine - analysis</subject><subject>Cinnarizine - blood</subject><subject>Cinnarizine - pharmacokinetics</subject><subject>Cinnarizine assay</subject><subject>Cinnarizine photo- and acid-degradation products</subject><subject>Densitometry</subject><subject>Female</subject><subject>General pharmacology</subject><subject>High performance liquid chromatography</subject><subject>Histamine H1 Antagonists - analysis</subject><subject>Histamine H1 Antagonists - blood</subject><subject>Histamine H1 Antagonists - pharmacokinetics</subject><subject>Indicators and Reagents</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Solubility</subject><subject>Spectrophotometry, Infrared</subject><subject>Spectrophotometry, Ultraviolet</subject><subject>Tablet dissolution rate</subject><subject>Tablets</subject><subject>Therapeutic Equivalency</subject><subject>Thin layer densitometry</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMouq7-BKUXRQ_VTNOm2ZPI4hcsKLiCt5CmE4xs05q0gv56sx_o0dPM4ZmZdx5CjoBeAAV--UxLBmlJRXFG4ZxSzrNUbJERiJKlGc9ft8noF9kj-yG8U0oLmOS7ZA8ySgUUMCJPs2miXJ3MY62xR99Yp3rbuqQ1ibbOKW-_rcPEuqR7U75RGofearVIOo-d8is4rHYE9ENzQHaMWgQ83NQxebm9mU_v09nj3cP0epZqNoE-pipyI4RBk8dvYh6uClCxYVWZ08xUDLXIc8UrI2rDFJvUkFUlgmFQclOzMTld7-18-zFg6GVjg8bFQjlshyBL4AJYxiJYrEHt2xA8Gtl52yj_JYHKpUq5UimXniQFuVIpRZw73hwYqgbrv6mNuwicbAAVog_jldM2_HGMi6wEGrmrNYdRx6dFL4O26DTW1qPuZd3af6L8AK02j60</recordid><startdate>20020515</startdate><enddate>20020515</enddate><creator>Hassan, Saad S.M</creator><creator>Elmosallamy, Mohamed A.F</creator><creator>Abbas, Alaa B</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020515</creationdate><title>LC and TLC determination of cinnarizine in pharmaceutical preparations and serum</title><author>Hassan, Saad S.M ; Elmosallamy, Mohamed A.F ; Abbas, Alaa B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-7054f88fef40161206a51a6123b7402fb3ec844a6bf8df3a39d12b7e1f3176fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Analysis</topic><topic>Animals</topic><topic>Bioavailability</topic><topic>Bioequivalency</topic><topic>Biological and medical sciences</topic><topic>Calibration</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Chromatography, Thin Layer</topic><topic>Cinnarizine - analysis</topic><topic>Cinnarizine - blood</topic><topic>Cinnarizine - pharmacokinetics</topic><topic>Cinnarizine assay</topic><topic>Cinnarizine photo- and acid-degradation products</topic><topic>Densitometry</topic><topic>Female</topic><topic>General pharmacology</topic><topic>High performance liquid chromatography</topic><topic>Histamine H1 Antagonists - analysis</topic><topic>Histamine H1 Antagonists - blood</topic><topic>Histamine H1 Antagonists - pharmacokinetics</topic><topic>Indicators and Reagents</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Solubility</topic><topic>Spectrophotometry, Infrared</topic><topic>Spectrophotometry, Ultraviolet</topic><topic>Tablet dissolution rate</topic><topic>Tablets</topic><topic>Therapeutic Equivalency</topic><topic>Thin layer densitometry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hassan, Saad S.M</creatorcontrib><creatorcontrib>Elmosallamy, Mohamed A.F</creatorcontrib><creatorcontrib>Abbas, Alaa B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hassan, Saad S.M</au><au>Elmosallamy, Mohamed A.F</au><au>Abbas, Alaa B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LC and TLC determination of cinnarizine in pharmaceutical preparations and serum</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2002-05-15</date><risdate>2002</risdate><volume>28</volume><issue>3</issue><spage>711</spage><epage>719</epage><pages>711-719</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>New high performance liquid chromatography (HPLC) and thin layer densitometry (TLC) methods are developed for quantification of cinnarizine in dosage forms in the presence of its photo-degradation products and related substances and in the presence of its metabolites in serum. Mobile phases consisting of benzene–methanol–formic acid (80:17:3) and methanol–acetate buffer of pH 4 (70:30) are satisfactorily used for resolution of cinnarizine from associated substances by TLC and HPLC techniques, respectively. The lower detection limits are 16 and 10 ng μl
−1 of cinnarizine with standard deviations of 1.3 and 1.1% with TLC and HPLC, respectively. The methods are used for assessment of drug purity, stability, bioavailability, bioequivalency and tablet dissolution rate. Four cinnarizine related substances and six drug degradation products are isolated and identified by infrared and mass spectrometry. The results obtained by both techniques are in good agreement and offer the advantages of reproducibility and accuracy.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>12008151</pmid><doi>10.1016/S0731-7085(01)00662-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0731-7085 |
| ispartof | Journal of pharmaceutical and biomedical analysis, 2002-05, Vol.28 (3), p.711-719 |
| issn | 0731-7085 1873-264X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71681323 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analysis Animals Bioavailability Bioequivalency Biological and medical sciences Calibration Chromatography, High Pressure Liquid Chromatography, Thin Layer Cinnarizine - analysis Cinnarizine - blood Cinnarizine - pharmacokinetics Cinnarizine assay Cinnarizine photo- and acid-degradation products Densitometry Female General pharmacology High performance liquid chromatography Histamine H1 Antagonists - analysis Histamine H1 Antagonists - blood Histamine H1 Antagonists - pharmacokinetics Indicators and Reagents Kinetics Male Medical sciences Pharmacology. Drug treatments Rats Rats, Sprague-Dawley Solubility Spectrophotometry, Infrared Spectrophotometry, Ultraviolet Tablet dissolution rate Tablets Therapeutic Equivalency Thin layer densitometry |
| title | LC and TLC determination of cinnarizine in pharmaceutical preparations and serum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A41%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LC%20and%20TLC%20determination%20of%20cinnarizine%20in%20pharmaceutical%20preparations%20and%20serum&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Hassan,%20Saad%20S.M&rft.date=2002-05-15&rft.volume=28&rft.issue=3&rft.spage=711&rft.epage=719&rft.pages=711-719&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/S0731-7085(01)00662-8&rft_dat=%3Cproquest_cross%3E71681323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71681323&rft_id=info:pmid/12008151&rft_els_id=S0731708501006628&rfr_iscdi=true |